Although angiotensin II has long been considered to represent the end product of the renin-angiotensin system (RAS), there is accumulating evidence that it encompasses additional effector peptides with diverse functions. In this respect, angiotensin IV (Ang IV) formed by deletion of the two N terminal amino acids, has sparked great interest because of its wide range of physiological effects. Among those, its facilitatory role in memory acquisition and retrieval is of special therapeutic relevance. High affinity binding sites for this peptide have been denoted as 'AT 4receptors' and, very recently, they have been proposed to correspond to the membrane-associated OTase/ IRAP aminopeptidase. This offers new opportunities for examining physiological roles of Ang IV in the fields of cognition, cardiovascular and renal metabolism and pathophysiological conditions like diabetes and hypertension. Still new recognition sites may be unveiled for this and other angiotensin fragments. Recognition sites for Ang-(1-7) (deletion of the C terminal amino acid) are still elusive and some of the actions of angiotensin III (deletion of the N terminal amino acid) in the CNS are hard to explain on the basis of their interaction with AT 1 -receptors only. A more thorough cross-talk between in vitro investigations on native and transfected cell lines and in vivo investigations on healthy, diseased and transgenic animals may prove to be essential to further unravel the molecular basis of the physiological actions of these small endogenous angiotensin fragments.
Introduction
The renin-angiotensin system (RAS) is widely recognised as the most powerful signalling system for controlling sodium balance, body fluid volumes and arterial blood pressure. Its major peptide, angiotensin II (Ang II), is formed by enzymatic processing of angiotensin I (Ang I) by the angiotensin-converting enzyme (ACE) in plasma, as well as in tissues such as the brain, kidney and heart. 1 Ang II is well known for its hypertensive effect and its ability to stimulate cardiac remodelling. Receptors of the AT 1 subtype play a major role in these processes. [2] [3] [4] AT 2 -receptors constitute the other major Ang II receptor subtype.They are expressed in fetal tissues and, in adulthood, they may also participate in blood pressure (BP) regulation.They may also be involved in the inhibition of cell proliferation, as well as in apoptosis and neuronal differentiation, but the underlying intra-cellular signalling pathways are not as well defined as for the AT 1 -receptor. 4, 5 Although Ang II has long been considered to represent the end product of the RAS, there is accumulating evidence that this system encompasses additional effector peptides with diverse functions. In this respect, shorter Ang II fragments such as Ang-(1-7) (deletion of the C terminal amino acid), angiotensin III (Ang III) (deletion of the N terminal amino acid) and angiotensin IV (Ang IV) (deletion of the two N terminal amino acids) are formed via the activity of ACE and several other peptidases ( Figure 1 ) and have been found to accomplish central, cardiovascular and renal actions. [6] [7] [8] [9] [10] [11] dose-dependent inhibition of tubular sodium reabsorption. 27 Ang IV is also active at the vascular level, since internal carotid or renal infusion of Ang IV increased cerebral and renal cortical blood flow. [36] [37] [38] [39] This vasodilator response was blocked by the nitric oxide (NO) synthase inhibitor, L-NAME. Studies on the pulmonary vasculature also suggested that Ang IV produces an endotheliumdependent vasodilatation in association with increased endothelial NO synthase activity and cGMP content. 40, 41 In addition, Ang IV promoted the release of vasodilatating prostaglandins. 42 Taken together, AT 4 -receptor stimulation may oppose the effects of AT 1 -receptor activation in the same way as AT 2 -receptor stimulation, and play a role in the regulation of renal haemodynamics (through interaction with endothelial NO release) and of sodium reabsorption.
At the molecular level, Ang IV interacts with AT 1 -and AT 2 -receptors, but only with low affinity (EC 50 within the micromolar range). 43, 44 Yet, most of its physiological effects are already observed at nanomolar concentrations and, most importantly, these are not blocked by the classical non-peptide AT 1 -and AT 2 -receptor antagonists, losartan and PD 123177. This, together with the discovery of binding sites with high affinity for [ 125 I]-Ang IV in the central nervous, vascular and renal systems 36, 30, 45 has led to the concept of a novel angiotensin receptor subtype: the 'AT 4 -receptor'. 4, 46 The pharmacological profile of this receptor subtype deviates significantly from AT 1 -and AT 2 -receptors, as it only displays very low affinity for Ang II and for AT 1 -and AT 2 -receptor antagonists. 36, [47] [48] [49] [50] Instead, it is activated by Ang IV and by more stable synthetic peptide analogues, such as Norleucine l -Ang IV (Nle l -Ang IV) 35, 51 and Norleucinal. 35 Divalinal-Ang IV is generally regarded to act as an AT 4 -receptor antagonist, but this issue remains controversial as it may elicit the same response as Ang IV in some systems. 28 AT 4 -receptors may also constitute cellular targets for other peptides like haemorphins, a class of endogenous peptides obtained by hydrolysis of the beta chain of haemoglobin. [52] [53] [54] As the concentration of Ang IV in brain is very low, it has been suggested that LVV-haemorphin-7 is a native ligand for the AT 4 -receptor. 52 AT 4 
Figure 1
Overview of the chemical structure and the enzymes involved in the synthesis of Ang II and its different fragments (according to 7, 9 ) effects of Ang IV and the presence of binding sites with high affinity for this peptide.The existence of such receptors is also supported by the ability of Ang IV to trigger biochemical events within different cell types. In this respect,Ang IV was found to stimulate a transient increase in [Ca 2+ ] i in cells of pulmonary, cardiac and renal origin. [60] [61] [62] In porcine aortic endothelial cells, the increase in [Ca 2+ ] i was found to trigger the production of NO and cGMP. 11, 40, 63 In addition,Ang IV has been found to stimulate DNA synthesis in the human neuroblastoma SK-N-MC cell line, as well as in coronary venous endothelial cells, 50, 64 to stimulate kinase p38 activity and to increase the level of phosphorylated Erk-2 and [Na + ] i in human proximal tubule epithelial cells 28 and to stimulate c-Fos expression in the hippocampus and piriform cortex. 22 Although the available information about AT 4receptor signalling is still far from complete, it appears that the involved pathways may differ from one cell type to another. 50, 64, 65 Most importantly, as 'classic' second messenger systems such as cAMP and inositol phosphates are largely unaffected, these signalling mechanisms do not appear to implicate the stimulation of G-proteins.
'OTase'/'IRAP' as an AT 4 -receptor candidate
Experiments involving the covalent labelling of AT 4 binding sites from bovine tissues and SK-N-MC cells consistently revealed the presence of a 165 kDa peptide. 45, 64, 66, 67 Whereas it was initially assumed to be a member of a growth factor or cytokine family of receptors, more elaborate experiments have provided compelling evidence that it corresponds to a membrane-associated aminopeptidase, formerly known as insulin-regulated aminopeptidase (IRAP), placental leucine aminopeptidase (P-LAP) and oxytocinase (OTase) ( Figure 2 ). 35 The different denominations of this enzyme are related to its independent 'discovery' by several research teams, as well as to differences in the physiological context in which they have been investigated. 'IRAP' (formerly known as gp160 and vp165) has been used to designate an enzyme of the rat. 'P-LAP', the major human placental protease, has been cloned recently 34, 68 and found to be identical to the formerly known cysteine aminopeptidase 'Otase'. 29 Based on the 87% homology of their amino acid sequences, OTase is regarded to be the human homologue of IRAP. Both are now commonly referred to as 'OTase/IRAP'. 34, 68, [69] [70] [71] [72] OTase/IRAP is a type II integral membrane protein homologous to aminopeptidase A (AP-A), aminopeptidase N (AP-N), and other Zn 2+ -dependent aminopeptidases included in the large family of gluzincin aminopeptidases. 34 It has a short intracellular domain, a single transmembrane-spanning domain and a large extracellular domain containing the catalytic site, which is able to cleave the Nterminal amino acid from several bioactive peptides in vitro (Figure 3 ). These peptides include Ang III and Ang IV, but their degradation is relatively slow compared with other peptides like vasopressin and Lys-bradykinin. 70 In this respect, RECENT ADVANCES IN THE RENIN-ANGIOTENSIN SYSTEM Figure 3 AT 1 -and AT 2 -receptors are members of the seven transmembrane guanyl nucleotide-binding protein (G-protein)coupled receptor superfamily. AT 1 -receptors stimulate the phosphoinositide signalling system, leading to an elevation of the intracellular free calcium concentration. 4 AT 2 -receptors have been found to activate protein tyrosine phosphatases. 55 Several pathways have been proposed by which AT 1 -receptors stimulate the MAP kinase pathway. 56,,57 IRAP is an integral membrane protein of 916 amino acid residues, consisting of an acidic intracellular region (109 amino acids) followed by a hydrophobic transmembrane segment (22 amino acid α-helix) and a 785 amino acid extracellular domain containing the enzymatic activity 31, 32, 58, 59, 74 ? ?
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Ang II Ang III Ang IV Ang-(1-7) experiments with OTase/IRAP-transfected cells reveal that Ang IV is a potent inhibitor of its enzymatic activity.The enzyme binds with high affinity to the Ang IV analogue, [ 125 I]Nle 1 -Ang IV, and can be selectively cross-linked with an Ang IV-related photoaffinity label. The correspondence between AT 4 binding sites and OTase/IRAP was further evidenced by the similar regional distribution of the enzyme's mRNA and immunoreactivity and the binding of [ 125 I]Nle 1 -Ang IV in thin sections of mouse brain. 35 OTase/IRAP was originally identified in GLUT4 vesicles. 32 These intracellular endosome-derived vesicles are best known for their property to carry GLUT4, an insulin-regulated glucose transporter that is abundantly expressed in muscle and adipose cells. 73 In contrast to many other transport vesicles, GLUT4 vesicles are only slowly translocated to the cell surface, where they fuse with the plasma membrane. Insulin increases their translocation rate, thereby shifting the distribution of GLUT4 from less than 10-15% on the surface to greater than 50%. [74] [75] [76] [77] [78] [79] Glucose uptake is increased proportionally and it is widely accepted that this redistribution of GLUT4 to the cell surface is a major mechanism by which insulin regulates glucose homeostasis. OTase/IRAP is redistributed to the plasma membrane in response to insulin in the same way as GLUT4, resulting in a large increase in the surface expression. 32, 58, 59, [80] [81] [82] [83] [84] [85] Reduced expression of GLUT4 has been found in various insulin-resistant states in humans and animals. 86 In this respect, Type 2 diabetes has clearly been associated with a decrease in GLUT4 concentration in adipocytes, as well as to a defect in GLUT4 trafficking/targeting in both skeletal muscle and adipocytes. 83, [87] [88] [89] OTase/IRAP has been found to exhibit the same trafficking/targeting defects in muscle and fat of Type 2 diabetic patients. 83, 88 Both are accumulated in a dense membrane compartment and can no longer be recruited to the cell surface by insulin.
By bringing OTase/IRAP to the cell surface, insulin has been proposed to modulate the activities of vasopressin, oxytocin and other peptide hormones and thereby broaden its own spectrum of action. 32 In this respect, defective translocation of OTase/IRAP in insulin-resistant individuals could cause a range of abnormalities and could be implicated in the cardiovascular complications of obesity and Type 2 diabetes, including hypertension or peripheral vascular disease. 32, [85] [86] [87] [88] [89] [90] A similar mechanism could also be involved in the cardiovascular complications of Type 1 diabetes, as insulin-deficient animals have been shown to lack OTase/IRAP function at the cell surface. 91 Alternatively, as vasopressin and oxytocin have been reported to stimulate insulin secretion in pancreatic cells, OTase/IRAP translocation could be involved as a negative feedback mechanism in glucose homeostasis. 69 OTase/IRAP is also the major human placental protease. Similar to ACE 92, 93 and other zinc metalloproteinases, its extracellular enzymatic part can be cleaved proteolytically and secreted. 34 It is note-worthy that the serum level of (secreted) OTase/IRAP increases with gestation and that oxytocin and vasopressin are major substrates of this enzyme. 29, [94] [95] [96] Since oxytocin and vasopressin have uterine contractive and vasoconstrictive activities,it has been postulated that OTase/IRAP contributes to the maintenance of normal pregnancy and suppresses labour pain by regulating the plasma level of these hormones. 29, 71, 72, 97 OTase/IRAP could also be part of a negative feedback mechanism, since oxytocin increases its activity at the cell surface in human umbilical vascular endothelial cells. 98 In this respect, serum levels of OTase/IRAP have been shown to be abnormally high in pregnancy-associated transient diabetes insipidus, a disease state characterised by polyuria. 99, 100 The elevated levels of this enzyme are likely to induce polyuria by increasing the metabolic clearance rate of vasopressin, leading to a reduction in water reabsorption by the renal collecting duct. 101 Northern blotting and immunoblotting indicate that OTase/IRAP has a broad tissue distribution. Besides adipocytes, skeletal muscle and placenta, this enzyme was also found to be present in rat heart, kidney, brain, spleen, lung and testis 32 and in human heart, kidney, brain and small intestine. 97 In rat brain, OTase/IRAP is present, along with GLUT4 and insulin or its receptors, in regions like hippocampus, cerebral cortex, basal ganglia, cerebellar cortex and medulla oblongata. 35, 97, 102 Similarly, AT 4 binding sites are also prominent in brain structures important to cognitive processing and sensory and motor functions, including neocortex, hippocampus, basal ganglia, thalamus, cerebellum and spinal cord. 15, 47 They have also been found in several peripheral tissues, including kidney, bladder, heart, spleen, prostate, adrenals and colon.
The control of the OTase/IRAP cell surface concentration and activity by Ang IV, insulin and other signalling molecules 73, 98 are points of special clinical interest. However, very little is known about these issues, especially since quantitative determinations of the OTase/IRAP concentration at the cell surface have hitherto been hindered by the requirement for laborious multi-step technical protocols. 85 Such determinations should now be greatly facilitated, and even be more accurate, with experiments involving the direct binding of radiolabelled Ang IV or its analogues.
Other AT 4 -receptors or a mixed enzyme/signalling role for OTase/IRAP?
Ang IV and LVV-haemorphin-7 inhibit the activity of IRAP. 35 It has therefore been suggested that at least part of their physiological effects could be related to the reduced processing of other peptide hormones. 35, 79 In the CNS, these ligands could extend the half-life of endogenous neuropeptides like vasopressin, substance P, and somatostatin, which are known to play important roles in cognitive function. 70, 103, 104 In the same line, an increased half-life of certain peptides, such as bradykinin, could be involved in mediating the NO-dependent responses to Ang IV. Alternatively, there is growing circumstantial evidence for OTase/IRAP to transfer extracellular information across the cell membrane in its own right; i.e. that it also acts as a classical receptor.At first glance, this seems hardly compatible with the classification of OTase/IRAP as an enzyme and with its three-dimensional structure comprising a single membrane-spanning α-helix. However, homodimer formation is one of the characteristic features of the membrane-bound M1 metallopeptidase family, 105 to which OTase/IRAP belongs.As a dimer, this enzyme could convey information across the cell membrane in the same way as growth factors and cytokine receptors. In this vein, it has already been shown that the structurally related AP-N (EC 3.4.11.2) and Dipeptidylpeptidase IV (DP IV, CD26, EC 3.4.14.3) have a similar subcellular location and dimeric structure and that they are able to mediate intracellular signalling. [106] [107] [108] [109] [110] Monoclonal antibodies towards AP-N triggered both IP 3 -receptor-linked Ca 2+ release and phosphorylation of the mitogenactivated protein kinases (Erk1/2, JNK and p38) in human monocytes. 110, 111 Similarly, DP IV appeared to be involved in T cell activation by potentiating the proliferative response after stimulation of the TcR/CD3 complex. 106, 112 It was also found to mediate early phosphorylation mechanisms in non-haematopoetic cells, such as hepatocarcinoma. 108 Interestingly, for the latter peptidase, the enzymatic activity was not required for its signalling. 113 A truncated DP IV, lacking the C-terminal catalytic domain, was still functional. 109 Synthetic inhibitors of the DP IV enzymatic activity were also capable of inducing intracellular tyrosine phosphorylation, transient MAP kinase p38 HOG activation, secretion of TGF-β1 and suppression of DNA synthesis and cytokine production in human and murine T cells. 114, 115 Together with the previous observations that the AT 4 -receptor mediates cellular events, such as an increase in [Ca 2+ ] i and phosphorylation of mitogen-activated protein kinases, it is obvious that the signalling properties of the OTase/IRAP system merits further exploration. In this context, it may be hypothesised that this system has a mixed enzyme/cell signalling function and maybe even a clearance function as described for the natriuretic peptides. 116, 117 Doubt may be raised whether the IRAP/AT 4 system represents the only cellular recognition site for Ang IV. In this respect, it was recently observed that the pre-activated human AT 1 -receptor displays high affinity for Ang IV and can be fully activated by this peptide. 43 The occurrence of such 'pre-activated' receptor conformation in in vivo situations has not yet been confirmed but it could explain why some of the effects of Ang IV were found to be susceptible to AT 1 -receptor blockade. 118, 119 
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Ang-(1-7) and Ang-(3-7)
Ang-(1-7) is another endogenous product of the RAS cascade in the vasculature, the CNS and the kidney. [120] [121] [122] [123] Although it was initially presumed to be inactive, it was recently reported to elicit phys-iological effects in these organs. These effects included stimulation of prostaglandin and NO release by endothelial cells, inhibition of vascular smooth muscle cell growth, vasodilatation, hypotension, potentiation of the hypotensive effects of bradykinin, stimulation of vasopressin release, facilitation of baroreflexes and stimulation of the glomerular filtration rate. [124] [125] [126] [127] [128] [129] Based on these effects,Ang-(1-7) may act as a negative feedback hormone of the pressor and trophic actions of Ang II. 121 In this context, it has even been proposed that ACE inhibitors (ACE-I) may exert their cardiovascular effects not only by blocking Ang II formation, but also by promoting the accumulation of Ang-(1-7). 130, 131 This proposal is based on observations that Ang- (1-7) is a substrate for ACE and that, with chronic ACE inhibition, circulating Ang II levels regained initial values after time, while the tissue levels of Ang-(1-7) increased several-fold (nine-fold in humans 132 ).
The existence of a specific receptor for Ang-(1-7) has been proposed to explain the non-classical (i.e. non AT 1 /AT 2 -receptor-related) behaviour of this heptapeptide in in vivo studies, isolated tissues and in intact cell systems. 6, 133 The putative 'AT(1-7)' receptor has been defined by its sensitivity to Ang-(1-7), its selective antagonism by [D-Ala 7 ]-Ang-(1-7) (A-779) and by its lack of sensitivity to standard AT 1 -and AT 2 -receptor antagonists. 134 However, despite the overwhelming number of reported actions of Ang- (1-7) , the identity and even the very existence of AT(1-7) receptors is still a matter of debate. In this respect, it is especially striking that only a few teams have reported the successful identification of AT(1-7) receptors by radioligand binding on membranes, or by autoradiography on tissue slices. 127, [134] [135] [136] [137] Alternative pathways and/or cellular recognition sites have been invoked to explain the physiological effects of Ang-(1-7) (Figure 3 ). In the first place, it should be mentioned that these have often been investigated in systems which also contain AT 1 -and/or AT 2 -receptors. However, Ang-(1-7) displays only weak affinity for these classical receptors and it even acts as an antagonist at the AT 1 -receptor. 43, [138] [139] [140] These findings exclude the intervention of AT 1 -and/or AT 2 -receptors in most of the effects of Ang- (1-7) .The question therefore remains why some of them were reported to be blocked by losartan or PD 123177. 141 Related to its degradation by ACE and presumably also by other peptidases, 142 the in vivo half-life of Ang-(1-7) in the circulation is only about 10 seconds. 131, 137 Ang-(1-7) is both a substrate and an inhibitor of ACE-I 17, 127, 143, 144 and this has led to the suggestion that some of its effects may actually be related to its binding to this enzyme, rather than to a specific receptor. Accordingly, Ang-(1-7) may act as a local synergistic modulator of bradykinininduced vasodilation by inhibiting its degradation by ACE. 143 Another possibility is that the potentiating effect of Ang-(1-7) may involve a direct crosstalk between ACE and the bradykinin B 2 -receptor. 144, 145 An even more provocative hypothesis allows ACE to act as a receptor in its own right.
Indeed, the potent ACE-I, captopril, 146 has been shown to inhibit proliferation of canine renal epithelial cells, human neuroblastoma cells, lung fibroblasts and mammary ductal carcinoma cells, [147] [148] [149] [150] to suppress the production of monocyte/macrophage-derived proinflammatory cytokines, [151] [152] [153] to inhibit Fas-induced apoptosis in human activated peripheral T cells and human lung epithelial cells and to inhibit activation-induced apoptosis in murine T cell hybridomas. [154] [155] [156] Finally, recent binding studies even suggest that it is not the radioligand [ 125 I]-Ang-(1-7) itself but one of its degradation products, [ 125 I]-Ang- (3) (4) (5) (6) (7) , that binds to kidney epithelial cell membranes and to kidney slices, and that the involved receptors are of the AT 4 -type. [157] [158] [159] In the CNS, the facilitatory effect of Ang-(3-7) on cognitive processes was shown to be mediated via the dopaminergic system with involvement of NMDA receptors. 160, 161 It is worth mentioning that both Ang-(3-7) and Ang IV decreased the MAP kinase/Erk signalling pathway in MDBK cells with high potency. 159 Whereas this explanation challenges the occurrence of specific Ang-(1-7) binding sites, it is clearly not sufficient to explain the effects of Ang-(1-7), especially since Ang-(3-7) is often less potent in comparative functional studies. 126, 157, 162 Angiotensin III Ang II and the heptapeptide Ang III (Ang-(2-8)) are both traditionally believed to act via AT 1 -and AT 2receptors ( Figure 3 ). Both peptides elicit similar physiological effects, such as stimulation of aldosterone secretion, vasoconstriction and dipsogenic activity. They also bind with similar affinity to the AT 1 -receptor and both peptides are equally potent agonists for this receptor. 43, 163 Ang III was shown to be at times even more effective than Ang II; for example,Ang III appeared twice as effective as Ang II in stimulating the firing rate of certain neurons. 164, 165 To deal with such findings, the question was raised years ago as to whether Ang III might be the predominant effector peptide in the brain rather than Ang II. 166 In the murine brain, Ang II is converted to Ang III by AP-A and Ang III is inactivated by AP-N. 167, 168 Based on this principle, experiments involving the i.c.v. administration of AP-A-and AP-N-selective inhibitors indicated that the modulation of the pressor response and vasopressin release induced by Ang II depends on its prior conversion to Ang III. [167] [168] [169] [170] The increases in vasopressin release and blood pressure (BP) induced by exogenous Ang II were inhibited when its conversion into Ang III was prevented by AP-A-selective inhibitors. Drinking and BP responses to i.c.v.-delivered Ang II could also be reduced by an antiserum with anti-catalytic activity against AP-A. 171 In the same line, the effects of Ang II on the firing rate of magnocellular neurons of the supraoptic nucleus of the rat could be prevented by central administration of the selective AP-A inhibitor, EC33. On the other hand, these responses were amplified when Ang III was allowed to accumulate with AP-N-selective inhibitors such as EC27.
These data raise the question as to why, if Ang II and Ang III have similar affinities for the AT 1 -receptor, the conversion of brain Ang II to Ang III is required to increase BP and vasopressin release.The presence of another unknown, AT 1 -like specific receptor for Ang III, with a pharmacological profile similar to that of the AT 1 -receptor, has been suggested. 172 In this respect, IRAP/P-LAP could represent an alternative candidate, as it is known to hydrolyse vasopressin and to display high affinity for Ang III. 70
Conclusions
It is now well established that Ang II is converted into a number of biologically active fragments (Figures 1 and 3) . Most attention has been focussed on their physiological effects in different organs. In this respect, the major metabolite, Ang IV, produces several central and vascular actions. Its cellular target, the so called 'AT 4 -receptor', 4 has recently been suggested to correspond to the OTase/IRAP enzyme. 35 This offers a wide range of new opportunities for examining the mechanisms of action of Ang IV in the fields of cognition, cardiovascular and renal metabolism and pathophysiological conditions, such as diabetes and hypertension. In this respect,Ang IV has been suggested to exert its physiological effects by inhibiting the metabolism of other bioactive peptides (e.g. vasopressin and oxytocin) by OTase/IRAP. However, based on recent findings with structurally related aminopeptidases, such as AP-N and dipeptidase IV, it is also plausible that OTase/IRAP is capable of triggering intracellular events in its own right. Although there is little doubt about the physiological relevance of Ang-(1-7), its cellular targets are still elusive. In the same line, doubt may be raised about whether OTase/IRAP represents the only cellular recognition site for Ang IV and whether additional, non AT 1 -/ non AT 2 -receptors may play a role in some of the central actions of Ang III. The existence of such additional cellular targets needs to be evaluated with due criticism but, as illustrated by the recent findings by Albiston et al., 35 their positive identification might be full of surprises.
The complexity of most of the hitherto used experimental systems, as well as to the instability of angiotensin fragments and related peptides, certainly contribute to the present uncertainties. Cell lines offer many advantages for the exploration of new recognition sites. Among them, ligand-receptor interactions can be investigated on the same cell type and under the same experimental conditions, both by radioligand binding and by measuring receptor-evoked responses. Transfected cell systems are also of interest, as the untransfected parent cells may serve as controls for the positive identification/exclusion of potential recognition sites.A more thorough cross-talk between such in vitro investigations and in vivo investigations on healthy, diseased and transgenic animals may prove to be essential to our understanding of the physiological role of endogenous angiotensin fragments like Ang IV.
Foundation
Belgium, the Fonds voor Wetenschappelijk
Onderzoek 
